NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper Buys 8,584 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director James N. Topper purchased 8,584 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were purchased at an average price of $19.50 per share, for a total transaction of $167,388.00. Following the completion of the acquisition, the director now owns 3,022,153 shares of the company’s stock, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $18.20 on Thursday. The firm has a market cap of $2.04 billion, a P/E ratio of -9.68 and a beta of -0.03. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The business has a 50-day moving average of $18.39 and a 200 day moving average of $20.82.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The business had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $1.46 million. As a group, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of large investors have recently made changes to their positions in NAMS. Legal & General Group Plc grew its holdings in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock valued at $590,000 after buying an additional 4,556 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $8,907,000. Swiss National Bank increased its position in shares of NewAmsterdam Pharma by 105.1% in the fourth quarter. Swiss National Bank now owns 72,000 shares of the company’s stock worth $1,850,000 after purchasing an additional 36,900 shares during the last quarter. Northern Trust Corp purchased a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $556,000. Finally, Barclays PLC raised its position in shares of NewAmsterdam Pharma by 120.0% during the 4th quarter. Barclays PLC now owns 16,713 shares of the company’s stock valued at $429,000 after buying an additional 9,117 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on NAMS. Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Citigroup started coverage on NewAmsterdam Pharma in a research report on Tuesday. They set a “buy” rating and a $42.00 price target for the company. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a “buy” rating and a $44.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Finally, Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.89.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.